Be higher in metastatic tumor cells compared to primary tumor cells

Be higher in metastatic tumor cells compared to primary tumor cells (P,0.06). Furthermore, recurrent osteosarcoma tissues tended to exhibit the highest FHL2 level (P,0.07 vs metastatic cells). Semi-quantitative analysis indicated that the FHL2 protein expression increases with tumor grade in human osteosarcoma and correlates with osteosarcoma aggressiveness (Fig. 1C). To confirm this finding, we determined the expression of FHL2 in the aggressive and highly metastatic murine (K7M2) osteosarcoma cells [20]. We found that FHL2 protein level was 2fold higher in K7M2 cells compared to normal murine C3H10T1/2 mesenchymal osteoprogenitors or to calvaria-derived MC3T3-E1 osteoblastic cells (Fig. 2A). Overall, these results suggest a role of FHL2 in osteosarcoma tumorigenesis.FHL2 Silencing Reduces Wnt/b-catenin Signaling in 23115181 Osteosarcoma CellsTo investigate whether FHL2 may be a molecular target in bone cancer cells we used short hairpin RNA (shRNA)-mediated inhibition of FHL2 expression in the model of K7M2 osteosarcoma cells [20]. We found that shFHL2 transduction in K7M2 cells decreased FHL2 expression by 50?0 compared to control cells transduced with a non relevant shRNA, as shown by qPCR and western blot GSK2606414 analyses (Fig. 2B, 2C). Using this tool, we examined the impact of shRNA-mediated inhibition of FHLFigure 1. Basal FHL2 expression in human osteosarcoma cells and in tissue microarrays (TMA) of human osteosarcomas. Whole cell lysates were probed 1527786 with the indicated antibody and revealed by Western blot analysis (A). FHL2 expression was determined by immunohistochemistry in tissue sections of normal bone, primary tumors, metastatic or recurrent osteosarcoma (Mag.6125) (B). Semiquantitative scoring of immunohistochemical staining with anti-FHL2 antibody in normal bone and osteosarcoma samples GSK2879552 site according toFHL2 Silencing Reduces Osteosarcoma Tumorigenesispatient outcome (primary tumor, metastatic or recurrent osteosarcoma) (C). *P,0.05. doi:10.1371/journal.pone.0055034.gexpression on osteocarcoma cells behavior. We found that FHL2 silencing reduced b-catenin nuclear translocation induced by Wnt3a in K7M2 cells, as shown by Western blot analysis (Fig. 2D), immunocytochemistry (Fig. 2E), and the reduced b-catenin transcriptional activity in the presence or absence of Wnt3a (Fig. 2F). To confirm the impact of FHL2 silencing on Wntsignaling in osteosarcoma cells, we performed a molecular analysis of Wnt responsive gene expression. We found that FHL2 silencing in K7M2 cells strongly decreased the expression of Axin2 and WISP-1 which are direct Wnt target genes [21] (Fig. 2G). FHL2 silencing also decreased the expression of c-Myc, which is involved in cell proliferation, and Wnt5a and Wnt10b, which are involved in osteosarcoma severity and invasiveness [22,23,24]. Furthermore, FHL2 silencing increased the expression of the Forkhead class box protein O transcription factor 1 (Foxo1), which is transcriptionally activated by b-catenin [25] (Fig. 2H). Overall,Figure 2. FHL2 silencing decreases Wnt/b-catenin signaling in osteosarcoma cells. Cell lysates of osteoblast precursor cell (C3H10T1/2), calvaria-derived osteoblastic cells (MC3T3E1) and osteosarcoma cell lines (K7M2) were analysed by western blot and FHL2 level was corrected for bactin (A). After transduction with shControl or shFHL2, FHL2 levels in K7M2 cells were evaluated by q-PCR (B) and Western blot analysis (C). shControl and shFHL2 transduced K7M2 cells were treated for 24 h with Wnt3a CM.Be higher in metastatic tumor cells compared to primary tumor cells (P,0.06). Furthermore, recurrent osteosarcoma tissues tended to exhibit the highest FHL2 level (P,0.07 vs metastatic cells). Semi-quantitative analysis indicated that the FHL2 protein expression increases with tumor grade in human osteosarcoma and correlates with osteosarcoma aggressiveness (Fig. 1C). To confirm this finding, we determined the expression of FHL2 in the aggressive and highly metastatic murine (K7M2) osteosarcoma cells [20]. We found that FHL2 protein level was 2fold higher in K7M2 cells compared to normal murine C3H10T1/2 mesenchymal osteoprogenitors or to calvaria-derived MC3T3-E1 osteoblastic cells (Fig. 2A). Overall, these results suggest a role of FHL2 in osteosarcoma tumorigenesis.FHL2 Silencing Reduces Wnt/b-catenin Signaling in 23115181 Osteosarcoma CellsTo investigate whether FHL2 may be a molecular target in bone cancer cells we used short hairpin RNA (shRNA)-mediated inhibition of FHL2 expression in the model of K7M2 osteosarcoma cells [20]. We found that shFHL2 transduction in K7M2 cells decreased FHL2 expression by 50?0 compared to control cells transduced with a non relevant shRNA, as shown by qPCR and western blot analyses (Fig. 2B, 2C). Using this tool, we examined the impact of shRNA-mediated inhibition of FHLFigure 1. Basal FHL2 expression in human osteosarcoma cells and in tissue microarrays (TMA) of human osteosarcomas. Whole cell lysates were probed 1527786 with the indicated antibody and revealed by Western blot analysis (A). FHL2 expression was determined by immunohistochemistry in tissue sections of normal bone, primary tumors, metastatic or recurrent osteosarcoma (Mag.6125) (B). Semiquantitative scoring of immunohistochemical staining with anti-FHL2 antibody in normal bone and osteosarcoma samples according toFHL2 Silencing Reduces Osteosarcoma Tumorigenesispatient outcome (primary tumor, metastatic or recurrent osteosarcoma) (C). *P,0.05. doi:10.1371/journal.pone.0055034.gexpression on osteocarcoma cells behavior. We found that FHL2 silencing reduced b-catenin nuclear translocation induced by Wnt3a in K7M2 cells, as shown by Western blot analysis (Fig. 2D), immunocytochemistry (Fig. 2E), and the reduced b-catenin transcriptional activity in the presence or absence of Wnt3a (Fig. 2F). To confirm the impact of FHL2 silencing on Wntsignaling in osteosarcoma cells, we performed a molecular analysis of Wnt responsive gene expression. We found that FHL2 silencing in K7M2 cells strongly decreased the expression of Axin2 and WISP-1 which are direct Wnt target genes [21] (Fig. 2G). FHL2 silencing also decreased the expression of c-Myc, which is involved in cell proliferation, and Wnt5a and Wnt10b, which are involved in osteosarcoma severity and invasiveness [22,23,24]. Furthermore, FHL2 silencing increased the expression of the Forkhead class box protein O transcription factor 1 (Foxo1), which is transcriptionally activated by b-catenin [25] (Fig. 2H). Overall,Figure 2. FHL2 silencing decreases Wnt/b-catenin signaling in osteosarcoma cells. Cell lysates of osteoblast precursor cell (C3H10T1/2), calvaria-derived osteoblastic cells (MC3T3E1) and osteosarcoma cell lines (K7M2) were analysed by western blot and FHL2 level was corrected for bactin (A). After transduction with shControl or shFHL2, FHL2 levels in K7M2 cells were evaluated by q-PCR (B) and Western blot analysis (C). shControl and shFHL2 transduced K7M2 cells were treated for 24 h with Wnt3a CM.